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The objective of welfare economics is to maximise population health from a fixed healthcare budget. 
To achieve this objective, economic evaluations of different healthcare interventions should 
consider all consequences related to healthcare, including future medical costs unrelated to the 
interventions.(1)    
 
The problem comes when trying to implement this approach in the real world. The utilitarian 
objective of maximising population health does not take into account whether health gains within 
the population are distributed fairly. 
In some situations, inclusion of unrelated costs would preclude specific groups of people from 
having equitable access to care. In these cases, decision makers should consider cost effectiveness 
analyses that exclude unrelated costs. 
A patient receiving dialysis 
The classic example cited to justify the exclusion of unrelated costs is that of a life extending 
treatment in a patient receiving dialysis where the treatment does not alter the need for lifelong 
dialysis.(2) If dialysis is expensive, and the quality of life of patients receiving dialysis is low, then the 
value of the life years gained by the treatment may not outweigh the cost of dialysis during those 
additional life years. In this situation, the life extending treatment would not be cost effective even if 
it were provided at zero cost.(3)  
 
Some health economists have argued that if the treatment being evaluated does not alter the need 
for lifelong dialysis, then the dialysis costs can be considered to be unrelated because the increased 
cost is driven solely by the increased longevity of the patient.(2) The exclusion of future dialysis costs 
on this basis allows cost effective prices to be identified for life extending treatments in this patient 
group. 
 
This situation may apply among any group of patients with high ongoing costs that cannot be 
reduced by better care. In the UK this may include people with high social care needs because of 
disability, because NICE requires costs met by personal and social services to be included in cost 
effectiveness analyses.(4)  
 
As a society we would never refuse to provide good preventive healthcare, such as flu vaccinations, 
to patients with disabilities purely because their high ongoing health and social care costs would 
mean that their early death would release funds that would generate more health gains elsewhere 
in the health system. A decision to do so would be unethical and would face legal challenges under 
ƚŚĞh< ?ƐĞƋƵĂůŝƚŝĞƐlegislation.(5)  
This same ethical argument can apply when considering interventions that are indicated only for 
groups of patients who need expensive ongoing care. It would be inequitable to fund technologies 
that are not themselves cost effective but to refuse to fund life extending treatments in populations 
receiving those cost ineffective technologies. The effect of such a decision would be to deny patients 
more of a treatment already prolonging their life when new patients would be able to receive it.(3) 
Healthcare systems have more than one purpose 
Some health economists might argue that more health would be gained by society as a whole if 
funding was removed from cost ineffective interventions and spent on cost effective interventions 
elsewhere in the healthcare system. However, the point here is that healthcare systems are not 
currently configured to maximise population health because that is not their only purpose. 
Society also values providing compassionate care to patients who cannot currently be cured, with 
the aim of maximising the health that can be achieved during their individual lifetimes. If the societal 
value of providing such care is not currently captured in cost effectiveness analyses, then excluding 
these costs as unrelated may be a means to appraise technologies in these populations in an 
equitable manner. It is for these reasons that NICE asks that unrelated future medical costs are 
omitted from cost effectiveness analyses. 
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